Loading
National Vision Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Aug 2024.
National Vision Holdings, Inc.: what insiders have been doing
Every trade that managers of National Vision Holdings, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 11 insiders have disclosed 33 filings since 18 October 2025.
All open-market trades in the period are sales: 1 sale worth €800k, by 1 insider, with no purchase on record. The largest single trade was a sale of €800k by Wilkes Alexander, published on 12 March 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 33 filings, this issuer sits above that mark. Since 2021, the database holds 13 purchases and 9 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 3 January 2026), the company reported revenue of 1.99 bn USD and net income of 29.6 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
183
Thresholds
n/a
Buy Volume
€5M
13 ops. · all time
Sell Volume
€3M
9 ops. · all time
Who traded when
BuySaleL. Reade Fahs2 sales
Alexander Wilkes1 sale
Megan Molony1 sale
Ravi Acharya1 sale
Since the insiders bought
- +105.7%Entry US$11.05 · Close at T+365 US$22.73
- +105.7%Entry US$11.05 · Close at T+365 US$22.73
- +16.2%Entry US$16.01 · Close at T+365 US$18.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 13,538 of 24,148 companies
48.1
score / 100
Value51
Quality45
FCF yld5.3%
Earn yld2.1%
EV/EBITDA13.1x
ROE5.8%
Gross mgn59%
Net mgn1.5%
Debt/EBITDA4.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$17.04
Analyst consensus
11 analysts1.58/5
US$20.00Target US$28.18(+65%)US$35.00
Income statement
RevenueUS$2B
Gross profitUS$1.2B59% margin
EBITDAUS$158.7M8% margin
Net incomeUS$29.6M2.5% margin
Valuation
PER (trailing)27.5x
PER (forward)14.1x
P/Book1.5x
Beta0.98
Balance sheet & cash
Market capUS$1.3B
Total debtUS$694.6M
Free Cash FlowUS$73.5M
Debt / Equity78%
Profitability & ownership
ROE5.8%
ROA2.9%
% insiders2.7%
% institutions130.0%
Last declaration on 9 September 2026
Declarations183 total
12,998 sharesCommon StockSEC:0002083693-26-000005:0
5,110 shares@ US$17.000.0066% mcap100.0% of flowCommon StockSEC:0002083693-26-000005:1
11,395 sharesCommon StockSEC:0002083688-26-000005:0
3,114 shares@ US$16.820.0040% mcap100.0% of flowCommon StockSEC:0002083688-26-000005:1
61,786 sharesCommon StockSEC:0002032275-26-000009:0
29,884 shares@ US$18.920.043% mcap34.5% of flowCommon StockSEC:0002032275-26-000009:1
6,660 shares@ US$22.040.011% mcap9.0% of flowCommon StockSEC:0002032275-26-000007:1
13,768 sharesCommon StockSEC:0002032275-26-000007:0
11,728 sharesCommon StockSEC:0002029231-26-000005:0
4,964 shares@ US$19.410.0074% mcap100.0% of flowCommon StockSEC:0002029231-26-000005:1
16,258 sharesCommon StockSEC:0001377480-26-000004:0
842 shares@ US$22.390.0012% mcap3.1% of flowCommon StockSEC:0001767639-26-000009:1
1,890 sharesCommon StockSEC:0001767639-26-000009:0
9,702 shares@ US$25.90100.0% of flowCommon StockSEC:0002058940-26-000004:1
26,082 sharesCommon StockSEC:0002058940-26-000004:0
35,000 shares@ US$26.5456.5% of flowCommon StockSEC:0002032275-26-000004:0
8,224 sharesCommon StockSEC:0002055495-26-000006:0
27,412 sharesCommon StockSEC:0002032275-26-000002:0
13,706 sharesCommon StockSEC:0002029231-26-000002:0
8,224 sharesCommon StockSEC:0001922081-26-000006:0
8,224 sharesCommon StockSEC:0001778111-26-000006:0
10,279 sharesCommon StockSEC:0001767639-26-000006:0
54,824 sharesCommon StockSEC:0001181253-26-000006:0
2,989 sharesCommon StockSEC:0002055495-26-000004:0
6,350 sharesCommon StockSEC:0001922081-26-000004:0
25 of 183 declarations
About National Vision Holdings, Inc.
National Vision Holdings, Inc. (ticker: EYE) is a U.S.-based specialty retailer in vision care, listed on the NASDAQ in the United States. The company operates a value-oriented model focused on making eye exams, eyeglasses, contact lenses, and related services more affordable and accessible. Its business sits at the intersection of healthcare and retail, combining in-store optical services with an omnichannel consumer platform.
National Vision’s roots trace back to National Vision, Inc., whose growth was built through acquisitions and network expansion. National Vision Holdings was incorporated in 2014, and the company completed its IPO in 2017. Headquartered in Duluth, Georgia, the group has developed around a relatively disciplined low-cost operating platform and a value proposition aimed at price-sensitive consumers. That positioning matters in the highly fragmented U.S. optical retail market, where competition comes from national chains, independent opticians, mass merchants, and online players.
Read moreShow less
The company’s operating model is built around four brands and channels: America’s Best, Eyeglass World, Vista Opticals located inside select Fred Meyer stores and on select military bases, and the e-commerce site DiscountContacts.com. Across these banners, National Vision sells prescription eyeglasses, contact lenses, eye exams, and various vision-care services. The mix of physical retail, professional eye-care services, and online replenishment gives the company multiple customer touchpoints and some recurring revenue characteristics, especially in contact lenses and lens-related products.
From a competitive standpoint, National Vision is positioned as a significant value player in the U.S. optical retail landscape, with a strategy that emphasizes store openings, traffic growth, and operational execution. Recent corporate messaging has highlighted a broader transformation plan designed to improve profitability, strengthen the company’s footprint in the estimated $70 billion U.S. optical retail market, and support more sustainable long-term growth. Recent earnings updates have pointed to improving comparable-store sales and margin trends, while management has also raised parts of its fiscal 2025 outlook and outlined longer-term financial objectives.
For French-speaking investors, EYE is best viewed as a U.S. consumer-health and specialty retail name rather than a pure healthcare provider. Its investment case is driven by execution on store productivity, pricing discipline, and the success of its multi-year transformation, all within the context of the NASDAQ-listed equity market in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
